Newcastle disease virus infectious clones, vaccines and new diagnostic assays
View Patent ↗The invention relates to the process for generating infectious Newcastle disease virus (NDV) entirely from cloned full-length cDNA and to the use of vaccines and diagnostic assays generated with and derived from said process. The process offers the possibility to modify the NDV genome by means of genetic modification and allows the introduction of mutations, deletions and/or insertions. The process can be used to modify the virulence of NDV, thereby generating new attenuated live vaccines with enhanced properties. The process can be used to modify the antigenic make-up of NDV, thus allowing the generation of live NDV marker vaccines which can be serologically distinguished from NDV field strains.
1. A method for assigning an animal to a group selected from:
(a) animals infected with wild-type Newcastle Disease Virus (NDV) or vaccinated with a first vaccine comprising an unmodified mesogenic or lentogenic NDV strain of NDV; and
(b) animals not infected with or vaccinated against NDV and animals vaccinated with a second vaccine comprising an infectious copy of an avian paramyxovirus at least partly derived from NDV obtainable by a process comprising: transfecting at least one cell with an avian-paramyxovirus cDNA comprising a nucleic acid sequence corresponding to the 5′-terminal end of the genome of avian paramyxovirus to generate an infectious copy of an avian pararmyxovirus, wherein said infectious copy of the avian-paramyxovirus encodes one or more viral proteins having a modification relative to wild-type or an unmodified mesogenic or lentogenic NDV strain, said method comprising:
providing a population of animals wherein one or more of the animals in said population has been vaccinated with said second vaccine;
taking at least one sample from an animal in said population to be assigned;
analyzing said at least one sample to determine the presence of antibodies directed against an epitope or marker expressed by an animal infected with wild-type NDV or vaccinated with said first vaccine, but not by an animal vaccinated with said second vaccine;
correlating the presence of antibodies directed against an epitope or marker expressed by an animal infected with wild-type NDV or vaccinated with said first vaccine, but not by an animal vaccinated with said second vaccine, with the animal not having been immunized with said second vaccine; and
assigning the animal to a group.
2. The method according to claim 1 wherein said antibodies directed against an epitope or marker expressed by wild-type or unmodified NDV, but not by said second vaccine are directed against an epitope on a hemaglutinin-neuraminidase or fusion protein of Newcastle Disease Virus.
3. The method according to claim 1 , wherein the modification is in a viral nucleocapsid, phospoprotein or large polymerase protein.
4. The method according to claim 1 wherein said animal is a chicken.
5. The method according to claim 2 wherein said animal is a chicken.
6. A diagnostic kit for use in a method according to claim 1 , said diagnostic kit comprising an antigen for reacting with said antibodies, wherein said antigen comprises an epitope or marker expressed by wild-type or unmodified Newcastle Disease Virus, but not by the vaccine.
7. The diagnostic kit of claim 6 , further comprising a vaccine specific antigen for reacting with said antibodies, wherein the vaccine specific antigen comprises an epitope expressed by the vaccine, but not the wild-type or unmodified Newcastle Disease Virus.
8. The diagnostic kit of claim 6 , wherein said infectious copy of an avian-paramyxovirus further comprises a nucleic acid encoding a heterologous antigen and said vaccine specific antigen comprises an epitope of said heterologous antigen.
9. The method according to claim 1 , wherein said Newcastle Disease Virus is a lentogenic virus.
10. The method according to claim 1 , wherein said modification comprises a modification of a structural protein.
11. The method according to claim 10 , wherein said modification comprises a modified protease cleavage site.
12. The method according to claim 11 , wherein said cleavage site is a protease cleavage site of the fusion protein.
13. The method according to claim 10 , wherein said modification comprises a modified hemaglutinin-neuraminidase protein.
14. The method according to claim 10 , wherein said modification comprises a modified matrix protein.
15. The method according to claim 1 , wherein said infectious copy of an avian-paramyxovirus further comprises a nucleic acid encoding a heterologous antigen.
16. The method according to claim 15 , wherein said heterologous antigen is derived from a poultry pathogen.